Kalohexis Taps Horizon Veteran to Steer Its Metabolic Disease Pipeline

NORTHBROOK, IL – August 11, 2026 – In a strategic move signaling significant ambition, clinical-stage biotechnology company Kalohexis, Inc. announced today it has appointed Dr. Jeffrey Sherman to its Board of Directors. The appointment of the former Horizon Therapeutics Chief Medical Officer is a clear indicator of the company's intent to accelerate its novel pipeline aimed at metabolic diseases, a space ripe for disruption but fraught with competitive and regulatory challenges.

For a company like Kalohexis, which spun out of Endevica Bio just this past March, securing a board member with Sherman's deep operational and regulatory acumen is more than a notable personnel change—it's a foundational play. The company is betting on its ability to harness the melanocortin system, the body's natural metabolic regulator, to develop treatments for both obesity and the devastating muscle-wasting syndrome, cancer cachexia. With Dr. Sherman's guidance, that bet just got a lot more credible.

A Masterclass in Biotech Strategy

To understand the gravity of this appointment, one need only look at Dr. Sherman's track record. His nearly 15-year tenure as EVP and CMO of Horizon Therapeutics saw the company transform from a promising player into a multi-billion-dollar powerhouse in rare and autoimmune diseases, culminating in its landmark acquisition by Amgen. He was instrumental in navigating the complex clinical and regulatory pathways that define success in the pharmaceutical industry. This isn't just about adding a big name to the letterhead; it's about embedding decades of hard-won experience into the company's DNA.

"Jeff is a distinguished industry leader who brings valuable experience in global clinical and regulatory strategy and rare disease drug development to Kalohexis' Board of Directors," said Russell Potterfield, Chief Executive Officer of Kalohexis, in the official announcement. "We are thrilled to welcome Jeff and look forward to leveraging his deep expertise as we advance our pipeline."

Sherman's experience extends beyond a single success story. His leadership at IDM Pharma led to the European approval of MEPACT® for a rare bone cancer, demonstrating a knack for steering specialized therapies through international regulatory bodies. His extensive board memberships, including roles at Larimar Therapeutics and Xeris Biopharma, position him as a sought-after advisor for clinical-stage companies at a critical inflection point. For Kalohexis, which is advancing a pipeline of therapeutic peptides, his expertise is a de-risking event, providing a steady hand to guide its assets through the treacherous waters of clinical trials and toward potential market approval.

The Promise of the Melanocortin System

At the heart of Kalohexis's strategy is the melanocortin system, a complex network of signals that governs appetite, energy expenditure, and inflammation. In his statement, Dr. Sherman called it a "powerful therapeutic axis that has been suboptimally targeted in the past." This is a polite way of saying that while the industry has known about its potential, few have managed to drug it safely and effectively.

The pathway's potential is validated by the success of Rhythm Pharmaceuticals' setmelanotide (IMCIVREE), an MC4R agonist approved for rare genetic obesity disorders. However, Kalohexis is pursuing a more nuanced, dual-pronged strategy by targeting both the melanocortin-3 and -4 receptors (MC3R/MC4R), which it believes can yield a more profound and safer metabolic impact.

The company’s pipeline showcases this dual approach. Its lead obesity candidate, 710GO, is an oral dual agonist designed to activate these receptors to induce healthier and more durable weight loss. The 'oral' aspect is a key differentiator in a market currently dominated by injectables. Its second lead program, mifomelatide, takes the opposite approach. As a dual antagonist, it aims to block the melanocortin receptors to combat cancer cachexia, a condition where metabolic dysregulation leads to severe, life-threatening weight loss. This demonstrates a sophisticated understanding of the system—knowing when to press the accelerator and when to apply the brakes.

"Kalohexis' proprietary know-how for safely and effectively targeting the melanocortin system... could offer new hope to millions of people with metabolic disorders," Dr. Sherman commented. His endorsement lends significant scientific and clinical weight to the company's approach, suggesting its technology may have overcome the historical challenges of targeting this system.

A Tale of Two Markets: Competition and Unmet Need

Kalohexis is stepping onto two very different playing fields. With its obesity candidate, 710GO, it enters one of the most competitive and lucrative markets in modern medicine. The landscape is dominated by GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Zepbound), which have set an incredibly high bar for efficacy. The global obesity treatment market is projected to skyrocket past $70 billion in the next decade, but any new entrant must offer a clear, compelling advantage, whether in efficacy, safety, or convenience. Kalohexis is betting that its novel mechanism and oral formulation will provide that edge.

Conversely, its cancer cachexia program with mifomelatide targets a devastating condition with a staggering unmet need. This syndrome affects a large percentage of patients with advanced cancer, and there are currently no universally approved, effective therapies. The market is smaller—projected to reach around $3 billion by 2030—but the opportunity to deliver a first-in-class treatment is immense. Success here would not only be a major humanitarian victory but also a massive commercial success. This dual-market strategy is a clever hedge: a high-risk, high-reward shot in a crowded obesity market balanced by a high-need, lower-competition opportunity in cachexia. Dr. Sherman’s extensive background in rare disease drug development provides Kalohexis with an invaluable strategic asset as it pursues the latter.

By bringing Dr. Sherman into the fold, Kalohexis is not just adding an advisor; it's making a statement about its readiness to transition from a promising spin-out to a major contender in metabolic disease. The path for any clinical-stage biotech is long and uncertain, but with veteran leadership and a scientifically robust strategy, Kalohexis has significantly improved its odds of shaping the next era of metabolic care.